130 related articles for article (PubMed ID: 36509070)
1. Beyond Median Overall Survival: Estimating Trends for Multiple Survival Scenarios in Patients With Metastatic Esophagogastric Cancer.
Pape M; Kuijper SC; Vissers PAJ; Beerepoot LV; Creemers GJ; van Laarhoven HWM; Verhoeven RHA
J Natl Compr Canc Netw; 2022 Dec; 20(12):1321-1329.e4. PubMed ID: 36509070
[TBL] [Abstract][Full Text] [Related]
2. Trends in best-case, typical and worst-case survival scenarios of patients with non-metastatic esophagogastric cancer between 2006 and 2020: A population-based study.
Kuijper SC; Pape M; Vissers PAJ; Jeene PM; Kouwenhoven EA; Haj Mohammad N; Ruurda JP; Sosef MN; Verhoeven RHA; van Laarhoven HWM
Int J Cancer; 2023 Jul; 153(1):33-43. PubMed ID: 36855965
[TBL] [Abstract][Full Text] [Related]
3. How long have I got? Estimating typical, best-case, and worst-case scenarios for patients starting first-line chemotherapy for metastatic breast cancer: a systematic review of recent randomized trials.
Kiely BE; Soon YY; Tattersall MH; Stockler MR
J Clin Oncol; 2011 Feb; 29(4):456-63. PubMed ID: 21189397
[TBL] [Abstract][Full Text] [Related]
4. Informing metastatic colorectal cancer patients by quantifying multiple scenarios for survival time based on real-life data.
Hamers PAH; Elferink MAG; Stellato RK; Punt CJA; May AM; Koopman M; Vink GR
Int J Cancer; 2021 Jan; 148(2):296-306. PubMed ID: 32638384
[TBL] [Abstract][Full Text] [Related]
5. Estimating scenarios for survival time in men starting systemic therapies for castration-resistant prostate cancer: a systematic review of randomised trials.
West TA; Kiely BE; Stockler MR
Eur J Cancer; 2014 Jul; 50(11):1916-24. PubMed ID: 24825113
[TBL] [Abstract][Full Text] [Related]
6. Accuracy and Prognostic Significance of Oncologists' Estimates and Scenarios for Survival Time in Advanced Gastric Cancer.
Vasista A; Stockler M; Martin A; Pavlakis N; Sjoquist K; Goldstein D; Gill S; Jain V; Liu G; Kannourakis G; Kim YH; Nott L; Snow S; Burge M; Harris D; Jonker D; Chua YJ; Epstein R; Bonaventura A; Kiely B
Oncologist; 2019 Nov; 24(11):e1102-e1107. PubMed ID: 30936377
[TBL] [Abstract][Full Text] [Related]
7. More than just the median: Calculating survival times for patients with HER2 positive, metastatic breast cancer using data from recent randomised trials.
Vasista A; Stockler MR; West T; Wilcken N; Kiely BE
Breast; 2017 Feb; 31():99-104. PubMed ID: 27829202
[TBL] [Abstract][Full Text] [Related]
8. Incidence and survival of patients with oligometastatic esophagogastric cancer: A multicenter cohort study.
Kroese TE; Christ SM; van Rossum PSN; Burger MDL; Buijs GS; Mühlematter U; Andratschke N; Ruurda JP; Hüllner M; Gutschow CA; van Hillegersberg R; Guckenberger M
Radiother Oncol; 2022 Aug; 173():269-276. PubMed ID: 35753555
[TBL] [Abstract][Full Text] [Related]
9. Heterogeneity of first-line palliative systemic treatment in synchronous metastatic esophagogastric cancer patients: A real-world evidence study.
Dijksterhuis WPM; Verhoeven RHA; Slingerland M; Haj Mohammad N; de Vos-Geelen J; Beerepoot LV; van Voorthuizen T; Creemers GJ; van Oijen MGH; van Laarhoven HWM
Int J Cancer; 2020 Apr; 146(7):1889-1901. PubMed ID: 31340065
[TBL] [Abstract][Full Text] [Related]
10. Conditional relative survival in nonmetastatic esophagogastric cancer between 2006 and 2020: A population-based study.
Pape M; Kuijper SC; Vissers PAJ; Ruurda JP; Neelis KJ; van Laarhoven HWM; Verhoeven RHA
Int J Cancer; 2023 Jun; 152(12):2503-2511. PubMed ID: 36840612
[TBL] [Abstract][Full Text] [Related]
11. Estimating typical, best-case and worst-case life expectancy scenarios for patients starting chemotherapy for advanced non-small-cell lung cancer: a systematic review of contemporary randomized trials.
Kiely BE; Alam M; Blinman P; Tattersall MH; Stockler MR
Lung Cancer; 2012 Sep; 77(3):537-44. PubMed ID: 22609149
[TBL] [Abstract][Full Text] [Related]
12. Increased assessment of HER2 in metastatic gastroesophageal cancer patients: a nationwide population-based cohort study.
Dijksterhuis WPM; Verhoeven RHA; Meijer SL; Slingerland M; Haj Mohammad N; de Vos-Geelen J; Beerepoot LV; van Voorthuizen T; Creemers GJ; van Oijen MGH; van Laarhoven HWM
Gastric Cancer; 2020 Jul; 23(4):579-590. PubMed ID: 31927675
[TBL] [Abstract][Full Text] [Related]
13. Trends in treatment and overall survival among patients with proximal esophageal cancer.
de Vos-Geelen J; Geurts SM; van Putten M; Valkenburg-van Iersel LB; Grabsch HI; Haj Mohammad N; Hoebers FJ; Hoge CV; Jeene PM; de Jong EJ; van Laarhoven HW; Rozema T; Slingerland M; Tjan-Heijnen VC; Nieuwenhuijzen GA; Lemmens VE
World J Gastroenterol; 2019 Dec; 25(47):6835-6846. PubMed ID: 31885424
[TBL] [Abstract][Full Text] [Related]
14. [Evaluation of the value of 7th editions of UICC-AJCC esophageal and gastric cancer TNM staging systems for prognostic prediction of adenocarcinoma of esophagogastric junction (Siewert type II)].
Shi GD; Luo ZL; Fu MY; Tian D; Zhang L; Zhang KP
Zhonghua Zhong Liu Za Zhi; 2014 Dec; 36(12):916-21. PubMed ID: 25623766
[TBL] [Abstract][Full Text] [Related]
15. CabaGast: multicentre, Phase II study with cabazitaxel in previously treated patients with advanced or metastatic adenocarcinoma of the esophagogastric junction and stomach.
Schmalenberg H; Al-Batran SE; Pauligk C; Zander T; Reichart A; Lindig U; Kleiß M; Müller L; Bolling C; Seufferlein T; Reichardt P; Kullmann F; Eschenburg H; Schmittel A; Egger M; Block A; Goetze TO
J Cancer Res Clin Oncol; 2018 Mar; 144(3):559-569. PubMed ID: 29285668
[TBL] [Abstract][Full Text] [Related]
16. Resection of hepatic and pulmonary metastasis from metastatic esophageal and gastric cancer: a nationwide study.
Seesing MFJ; van der Veen A; Brenkman HJF; Stockmann HBAC; Nieuwenhuijzen GAP; Rosman C; van den Wildenberg FJH; van Berge Henegouwen MI; van Duijvendijk P; Wijnhoven BPL; Stoot JHMB; Lacle M; Ruurda JP; van Hillegersberg R;
Dis Esophagus; 2019 Dec; 32(12):. PubMed ID: 31220859
[TBL] [Abstract][Full Text] [Related]
17. SOURCE: Prediction Models for Overall Survival in Patients With Metastatic and Potentially Curable Esophageal and Gastric Cancer.
van den Boorn HG; Abu-Hanna A; Haj Mohammad N; Hulshof MCCM; Gisbertz SS; Klarenbeek BR; Slingerland M; Beerepoot LV; Rozema T; Sprangers MAG; Verhoeven RHA; van Oijen MGH; Zwinderman KH; van Laarhoven HWM
J Natl Compr Canc Netw; 2021 Apr; 19(4):403-410. PubMed ID: 33636694
[TBL] [Abstract][Full Text] [Related]
18. Long-term survival in patients with metastatic gastric and gastroesophageal cancer treated with surgery.
Badgwell B; Roy-Chowdhuri S; Chiang YJ; Matamoros A; Blum M; Fournier K; Mansfield P; Ajani J
J Surg Oncol; 2015 Jun; 111(7):875-81. PubMed ID: 25872485
[TBL] [Abstract][Full Text] [Related]
19. A pilot study assessing the incidence and clinical significance of circulating tumor cells in esophagogastric cancers.
Sclafani F; Smyth E; Cunningham D; Chau I; Turner A; Watkins D
Clin Colorectal Cancer; 2014 Jun; 13(2):94-9. PubMed ID: 24332356
[TBL] [Abstract][Full Text] [Related]
20. A reliable risk score for stage IV esophagogastric cancer.
Blank S; Lordick F; Dobritz M; Grenacher L; Burian M; Langer R; Roth W; Schaible A; Becker K; Bläker H; Sisic L; Stange A; Compani P; Schulze-Bergkamen H; Jäger D; Büchler M; Siewert JR; Ott K
Eur J Surg Oncol; 2013 Aug; 39(8):823-30. PubMed ID: 23375470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
